Pulse Biosciences stock gets a higher fair value estimate

Published on 10/06/2026 at 07:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulse Biosciences stock drew a USD 54.00 fair value on October 3, 2026. Second-quarter revenue was USD 434,000 versus USD 530,000 expected.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences stock drew a higher fair value estimate after analysts cited clinical data and upcoming milestones. Yahoo Finance reported on October 3, 2026, that the estimate moved from USD 45.25 to USD 54.00 per share. The revision puts clinical validation and regulatory execution at the center of the investment case.

Fair value reaches USD 54.00

The Yahoo Finance report said BTIG cited first-in-human European data from 141 patients, including procedural success of 100.00 percent at six months and 96.20 percent at 12 months. BTIG's reported price target was USD 70.00, while Canaccord moved its target from USD 32.00 to USD 43.00, Mizuho from USD 30.00 to USD 45.00, and Oppenheimer from USD 30.00 to USD 35.00.

The same report also identified validation risk because early nanosecond pulsed field ablation data still require confirmation in pivotal trials. That distinction matters: the valuation reset reflects clinical evidence, while commercial scale and regulatory milestones remain separate execution tests.

Revenue remains an early-stage metric

Pulse Biosciences reported USD 434,000 of revenue in the second quarter of 2026, compared with a USD 530,000 consensus estimate, according to MarketBeat. The company posted a quarterly loss of USD 0.36 per share against an expected loss of USD 0.29, a shortfall of USD 0.07 per share.

Financial capacity provides a counterweight to the small revenue base. Cash and cash equivalents were USD 101.6 million at June 30, 2026, while operating cash flow was negative USD 18.7 million in the second quarter, according to the standardized financial statements for that period.

Clinical enrollment expands the pipeline

Pulse Biosciences said in a September 15, 2026 filing that it completed enrollment in the PRECISE-BTN study after expanding the design from 50 to 100 patients. The study evaluates the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules, with follow-up visits scheduled at one, three, six, and 12 months, according to the SEC filing.

The company describes its CellFX System as a commercial platform using proprietary Nano-Pulse Stimulation technology to affect targeted cells while sparing surrounding non-cellular tissue, according to its investor-relations profile. The current setup therefore combines a USD 54.00 fair value framework with a business that is still translating clinical progress into revenue.

Next report date is November 16

TradingView identifies Pulse Biosciences as a Nasdaq-listed company with ISIN US74587B1017 and lists November 16, 2026, as the next report date for the third quarter of 2026. On October 5, 2026, the market capitalization was USD 3.5 billion, and the 52-week range was USD 12.56 to USD 58.90.